Valuation : Intervacc AB

Market Cap 36Cr 3.8Cr 3.28Cr 3.07Cr 2.81Cr 5.29Cr 363.6Cr 5.3Cr 14Cr 183.55Cr 14Cr 14Cr 608.6Cr P/E 2026 *
-0.96x
P/E 2027 * -0.96x
Enterprise Value 28Cr 2.88Cr 2.48Cr 2.32Cr 2.12Cr 4Cr 274.86Cr 4.01Cr 11Cr 138.75Cr 11Cr 11Cr 460.07Cr EV / Sales 2026 *
13.1x
EV / Sales 2027 * 10.1x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-2.24%
1 week-3.68%
Current month-17.64%
1 month-15.92%
3 months-14.54%
6 months+69.26%
Current year+13.20%
1 week 1.02
Extreme 1.018
1.13
1 month 1
Extreme 0.999
1.35
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76.4
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
23/02/25 Free

Chief Financial Officer

9,29,208 1.2269%
17/02/25 Buy

Chief Executive Officer

1,35,000 0.1783%
17/02/25 Sell

Chief Executive Officer

2,78,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%-3.68%0.00%-75.04% 3.83Cr
-1.59%-6.25%+64.99%+99.09% 7.06TCr
-1.34%-0.75%+48.56%+90.63% 6.61TCr
-7.68%-11.89%+0.76%-14.89% 2.8TCr
-2.62%-5.93%-12.34%+447.22% 2.65TCr
+0.30%+2.03%+59.48%+14.21% 2.64TCr
-0.96%+12.36%+280.38%+439.54% 2.04TCr
-0.51%+0.23%+33.71%-18.02% 2.02TCr
-1.91%-3.47%+11.03%+508.52% 1.6TCr
-2.00%+0.11%+42.85%+144.09% 1.37TCr
Average -2.05%+0.70%+52.94%+163.54% 2.88TCr
Weighted average by Cap. -1.96%+1.22%+56.36%+151.10%

Financials

2026 *2027 *
Net sales 2.11Cr 22.01L 18.97L 17.78L 16.23L 30.58L 21Cr 30.68L 82.32L 11Cr 82.65L 80.85L 35Cr 3Cr 31.35L 27.01L 25.33L 23.12L 43.56L 30Cr 43.7L 1.17Cr 15Cr 1.18Cr 1.15Cr 50Cr
Net income -8.24Cr -86.02L -74.12L -69.49L -63.44L -1.2Cr -82Cr -1.2Cr -3.22Cr -41Cr -3.23Cr -3.16Cr -137.6Cr -8.36Cr -87.27L -75.2L -70.51L -64.36L -1.21Cr -83Cr -1.22Cr -3.26Cr -42Cr -3.28Cr -3.21Cr -139.61Cr
Net Debt -8.9Cr -92.85L -80.01L -75.02L -68.48L -1.29Cr -89Cr -1.29Cr -3.47Cr -45Cr -3.49Cr -3.41Cr -148.53Cr -6.1Cr -63.64L -54.84L -51.42L -46.93L -88.42L -61Cr -88.7L -2.38Cr -31Cr -2.39Cr -2.34Cr -101.8Cr
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
28/26/28 SEK 1.046 -2.24% 1,42,135
27/26/27 SEK 1.070 -0.56% 4,17,515
26/26/26 SEK 1.076 -1.82% 1,42,876
25/26/25 SEK 1.096 -2.84% 1,90,375
24/26/24 SEK 1.128 +3.87% 1,54,899

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock